1. Aims, Scope & Article Categories
Modern Pharmacy Praxis & Therapeutics (MPPT) is a peer-reviewed, open-access journal dedicated to clinical and experimental pharmaceutical sciences. We invite submissions under the following categories:
2. Manuscript Architecture
- Title Page: Concise, informative title (sentence case or title case, no abbreviations). Include full names of all authors, highest academic degrees, institutional affiliations, and the corresponding author's institutional email and ORCID iD.
- Structured Abstract (Max 250 Words): Formatted with explicit headings: Background, Methods, Results, and Conclusion. No citations or unexpanded abbreviations.
- Keywords: 4 to 6 MeSH-compliant (Medical Subject Headings) terms separated by semicolons.
- Body Sections: Introduction (problem statement & hypothesis), Materials & Methods (precise protocols to enable exact replication), Results & Discussion (statistical rigor, p-values, contextualization), and Conclusions.
- Back Matter: Acknowledgments, Funding Statements, Ethics Approval Protocol Number, Informed Consent statement, and Competing Interests disclosure.
3. Referencing Standards (Vancouver Style)
Citations must be numbered consecutively in order of appearance in the text using square brackets, e.g., [1] or [2–4]. Format reference entries according to NLM/Vancouver conventions:
1. Sharma A, Patel PV, Thorne DM. Targeted curcumin-loaded liposomes in neuroprotection. Mod Pharm Praxis Ther. 2026;1(1):14-22. doi:10.1016/j.mppt.2026.01.004
2. World Health Organization. Guidelines on Good Pharmacovigilance Practices. Geneva: WHO Press; 2024.
4. Figures, Tables & Plagiarism Policy
- Visual Resolution: Minimum 300 DPI for halftone/color photography; 600 DPI for line charts and structural chemical diagrams. TIFF, PNG, or vector EPS.
- Similarity Screening: All submissions are automatically screened with Turnitin / iThenticate upon desk receipt. Overall similarity must not exceed 15%, and single-source similarity must be strictly <3% (excluding bibliography).
- Peer Review Window: 14 to 21 days first editorial decision; double-blind evaluation by two doctoral-holding subject matter referees.
1. Ethical Governance & Regulatory Alignment
Modern Pharmacy Praxis & Therapeutics (MPPT) rigorously enforces the core practices of the Committee on Publication Ethics (COPE), the International Committee of Medical Journal Editors (ICMJE), and the World Association of Medical Editors (WAME).
2. Research Involving Human Participants & Animals
- Human Subjects & Declaration of Helsinki: All clinical trials, intervention studies, and human observational cohorts must comply with the World Medical Association Declaration of Helsinki. Formal clearance from an accredited Institutional Review Board (IRB) or Independent Ethics Committee (IEC) is mandatory. The ethics committee name, approval protocol number, and date of clearance must be explicitly cited in the Materials and Methods section.
- Patient Anonymity & Informed Consent: Written informed consent must be secured from all participants (or authorized guardians). Patient identifiers (names, hospital IDs, photographic likeness) must not be disclosed.
- Animal Welfare & CPCSEA/ARRIVE: In vivo experimental protocols must comply with CPCSEA / ARRIVE guidelines and specify local animal ethics committee approval numbers.
3. Authorship Criteria (ICMJE 4 Principles)
Authorship credit must be strictly reserved for individuals meeting all four ICMJE criteria:
- Substantial contributions to conception, design, acquisition, or analysis and interpretation of research data;
- Drafting the article or revising it critically for important intellectual content;
- Final approval of the version to be published;
- Agreement to be accountable for all aspects of the work in ensuring that questions related to integrity are appropriately investigated.
Ghost, guest, or gift authorship is strictly prohibited. Medical writers and contributors not meeting all 4 criteria must be acknowledged in the Acknowledgments section.
4. Generative AI & Large Language Models Policy
Generative artificial intelligence (AI) tools, such as Large Language Models (LLMs), cannot be credited as authors. Where AI tools were utilized to support code generation, statistical processing, or linguistic polishing, authors must transparently disclose the software name, version, and exact application within the Methods section.
5. Conflicts of Interest & Retraction Protocol
Authors must disclose all commercial, pharmaceutical, financial, or personal competing interests. If no conflict exists, declare: "The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper."
Post-publication expressions of concern, corrections (errata/corrigenda), and retractions will be executed in full accordance with COPE Retraction Guidelines in the event of documented data fabrication, falsification, or severe methodological invalidity.
1. Open Access Licensing (Creative Commons CC BY 4.0)
All articles published in Modern Pharmacy Praxis & Therapeutics (MPPT) are open access and published under the Creative Commons Attribution 4.0 International License (CC BY 4.0).
Under this license, authors, readers, and institutions worldwide are permitted to freely:
- Share: Copy and redistribute the material in any medium or format.
- Adapt: Remix, transform, and build upon the material for any purpose, even commercially.
- Attribution: You must give appropriate credit to the authors and MPPT, provide a link to the license, and indicate if changes were made.
2. Authors Retain Unrestricted Copyright
Authors retain unrestricted copyright of their intellectual property. Unlike traditional subscription journals, MPPT does not require authors to transfer copyright ownership. Authors grant MPPT a non-exclusive license for initial publication, digital archiving, and global indexation.
3. Self-Archiving & Repository Rights (Green Open Access)
Authors have the unencumbered right to deposit all versions of their manuscript:
- Preprint (Pre-refereeing): May be hosted on preprint servers (bioRxiv, medRxiv, ChemRxiv) at any time.
- Accepted Author Manuscript (AAM): May be deposited into institutional or subject repositories upon acceptance.
- Published Version of Record (Final PDF): May be deposited immediately upon publication without embargo, with proper DOI citation.
Official Author Warranty & Publication Agreement
Journal: Modern Pharmacy Praxis & Therapeutics (MPPT) · ISSN Online: 3048-xxxx
Declaration: I/We warrant that this manuscript is original, has not been published elsewhere, does not infringe upon any third-party copyright, and that all co-authors have consented to its submission and open-access publication under CC BY 4.0.
Corresponding Author:
Date:
Institutional Signature:
Official MPPT Manuscript Layout & Typography Template
Authors are encouraged to prepare their submissions using the standardized structural layout demonstrated below. Submissions must be formatted in single or double-column, 1.5 line spacing, 12pt serif font (Times New Roman / Georgia) with 1-inch margins.
Formulation and Optimization of Targeted Polymeric Nanoparticles for Sustained Therapeutic Delivery: Physicochemical Characterization and Pharmacokinetics
Aarav Sharma1, Priya V. Patel2*, David M. Thorne3
1 Department of Pharmaceutics, University College of Pharmaceutical Sciences, New Delhi, India
2 Department of Pharmacology, Faculty of Pharmacy, King’s College London, London, UK
3 Center for Nanomedicine & Drug Delivery, Johns Hopkins University, Baltimore, USA
* Corresponding Author:
[email protected]
ABSTRACT · Max 250 Words
Background: Poor oral bioavailability and rapid systemic clearance constrain the therapeutic efficacy of hydrophobic bioactives in chronic neuroinflammatory disorders.
Methods: PLGA-PEG nanoparticles were formulated via solvent displacement and optimized using Box-Behnken design. Mean hydrodynamic diameter, zeta potential, entrapment efficiency, and in vivo pharmacokinetics in Sprague-Dawley rats were evaluated.
Results: Nanoparticles exhibited mean diameter of 138.4 ± 4.2 nm (PDI 0.11), entrapment efficiency of 89.6 ± 2.1%, and sustained release over 72 h. Oral bioavailability increased 6.8-fold compared to unformulated suspension (p < 0.001).
Conclusion: The formulated polymeric nanocarrier provides a clinically translatable platform for oral sustained drug delivery.
KEYWORDS: Polymeric nanoparticles; Bioavailability; Drug delivery; Pharmacokinetics; Vancouver style
1. Introduction
Translational therapeutics increasingly demands delivery vectors capable of surmounting physiological barriers without precipitating systemic toxicity [1]. Conventional formulations frequently succumb to first-pass metabolism, precipitating sub-therapeutic serum titers.
2. Materials & Methods
PLGA (50:50 lactide:glycolide, MW 45,000) and PEG-3000 were sourced from Sigma-Aldrich. Nanoparticles were assembled via nanoprecipitation under constant stirring (800 rpm) at 25°C. Particle sizing was performed via Dynamic Light Scattering (Malvern Zetasizer Nano ZS) [2].
3. Results & Discussion
Formulation optimization demonstrated unimodal size distributions with high colloidal stability over 90 days at 4°C. In vivo plasma concentration-time profiles demonstrated significantly enhanced AUC0-∞ (p < 0.01) [3].
4. References (Vancouver)
- Sharma A, Patel PV. Nanocarriers in drug delivery. J Control Release. 2024;365:102-114.
- Thorne DM, et al. Colloidal kinetics of PLGA. Mol Pharm. 2025;22(2):312-320.
- Patel PV. Bioavailability enhancement. Pharm Res. 2025;42:45-53.
